Trial Designs

In the meantime, do check out what Prof Yaseen Arabi has to say about trial designs in the ICU for infectious diseases!

He was behind the MIRACLE trial – the first RCT for MERS treatment, looking at the combination of lopinavir/ritonavir and interferon-β1b back when MERS emerged.

Fast-forward to 2020, Prof Yaseen Arabi discusses the quick modifications made to the international REMAP-CAP Trial to accommodate COVID-19 – now termed REMAP-COVID.

Check out some of his articles here:

NEJM Special Report: Middle East Respiratory Syndrome

Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-β1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial

COVID-19: a novel coronavirus and a novel challenge for critical care